Literature DB >> 16270321

Five genes from chromosomal band 8p22 are significantly down-regulated in ovarian carcinoma: N33 and EFA6R have a potential impact on overall survival.

Dietmar Pils1, Peter Horak, Andreas Gleiss, Cornelia Sax, Gerhild Fabjani, Volker J Moebus, Christoph Zielinski, Alexander Reinthaller, Robert Zeillinger, Michael Krainer.   

Abstract

BACKGROUND: Loss of heterozygosity on chromosomal band 8p22 is a common event in several epithelial tumors including ovarian carcinoma. So far, no clear evidence for a tumor suppressor gene (TSG) in this region has been found.
METHODS: On the basis of publicly available expression data in ovarian tissues, the authors selected the eight most noteworthy genes from 8p22 (DLC1, N33, ZDHHC2, FLJ32642, PDGFRL, MTSG1, PCM1, and EFA6R) for a detailed expression analysis in 58 primary ovarian carcinoma tissues and in 38 ovarian cancer cell lines by using quantitative real-time reverse transcriptase-polymerase chain reaction (qRT-PCR). Expression data were correlated to various clinicopathologic characteristics and survival.
RESULTS: Two genes showed a significantly (P< 0.05) lower expression in grade 3 tumors compared with tumors of lower grade (N33) or compared with normal controls and tumors with lower grade (EFA6R). Expression of N33 and EFA6R seems to have an impact on survival, in particular when the combined expression of both genes was used as predictive factor (P< 0.003). In addition, N33 and EFA6R showed a complete loss of expression in several ovarian cancer cell lines. Three genes (FLJ32642, MTSG1, and PCM1) had a significantly (P< 0.001, P< 0.004, and P< 0.001) lower expression in primary ovarian carcinoma compared with controls (ovarian tissues and cysts).
CONCLUSIONS: Two to five new potential tumor suppressor or antagonizing gene candidates (N33 and EFA6R with impact on survival, and potentially FLJ32642, MTSG1, and PCM1) for ovarian carcinoma, were identified from the chromosomal band 8p22 and are promising candidates for further functional analysis in ovarian carcinoma.

Entities:  

Mesh:

Year:  2005        PMID: 16270321     DOI: 10.1002/cncr.21538

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  39 in total

1.  Reduced expression of MTUS1 mRNA is correlated with poor prognosis in bladder cancer.

Authors:  Jun Xiao; Jun-Xing Chen; Yu-Ping Zhu; Lin-Yu Zhou; Qi-An Shu; Ling-Wu Chen
Journal:  Oncol Lett       Date:  2012-04-05       Impact factor: 2.967

2.  Matching cancer genomes to established cell lines for personalized oncology.

Authors:  Joel T Dudley; Rong Chen; Atul J Butte
Journal:  Pac Symp Biocomput       Date:  2011

3.  Efa6 protects axons and regulates their growth and branching by inhibiting microtubule polymerisation at the cortex.

Authors:  Yue Qu; Ines Hahn; Meredith Lees; Jill Parkin; André Voelzmann; Karel Dorey; Alex Rathbone; Claire T Friel; Victoria J Allan; Pilar Okenve-Ramos; Natalia Sanchez-Soriano; Andreas Prokop
Journal:  Elife       Date:  2019-11-13       Impact factor: 8.140

Review 4.  TUSC3: functional duality of a cancer gene.

Authors:  Kateřina Vašíčková; Peter Horak; Petr Vaňhara
Journal:  Cell Mol Life Sci       Date:  2017-09-19       Impact factor: 9.261

5.  TUSC3 suppresses glioblastoma development by inhibiting Akt signaling.

Authors:  Zhenfeng Jiang; Mian Guo; Xiangtong Zhang; Lifen Yao; Jia Shen; Guizhen Ma; Li Liu; Liwei Zhao; Chuncheng Xie; Hongsheng Liang; Haiyang Wang; Minwei Zhu; Li Hu; Yuanyuan Song; Hong Shen; Zhiguo Lin
Journal:  Tumour Biol       Date:  2016-05-13

6.  8p22 MTUS1 gene product ATIP3 is a novel anti-mitotic protein underexpressed in invasive breast carcinoma of poor prognosis.

Authors:  Sylvie Rodrigues-Ferreira; Anne Di Tommaso; Ariane Dimitrov; Sylvie Cazaubon; Nadège Gruel; Hélène Colasson; André Nicolas; Nathalie Chaverot; Vincent Molinié; Fabien Reyal; Brigitte Sigal-Zafrani; Benoit Terris; Olivier Delattre; François Radvanyi; Franck Perez; Anne Vincent-Salomon; Clara Nahmias
Journal:  PLoS One       Date:  2009-10-01       Impact factor: 3.240

7.  An integrative multi-dimensional genetic and epigenetic strategy to identify aberrant genes and pathways in cancer.

Authors:  Raj Chari; Bradley P Coe; Emily A Vucic; William W Lockwood; Wan L Lam
Journal:  BMC Syst Biol       Date:  2010-05-17

8.  Predicting relapse in favorable histology Wilms tumor using gene expression analysis: a report from the Renal Tumor Committee of the Children's Oncology Group.

Authors:  Chiang-Ching Huang; Samantha Gadd; Norman Breslow; Colleen Cutcliffe; Simone T Sredni; Irene B Helenowski; Jeffrey S Dome; Paul E Grundy; Daniel M Green; Michael K Fritsch; Elizabeth J Perlman
Journal:  Clin Cancer Res       Date:  2009-02-10       Impact factor: 12.531

9.  Genomic assessments of the frequent loss of heterozygosity region on 8p21.3-p22 in head and neck squamous cell carcinoma.

Authors:  Hui Ye; Nisa Pungpravat; Bau-Lin Huang; Lorenzo L Muzio; Maria A Mariggiò; Zugen Chen; David T Wong; Xiaofeng Zhou
Journal:  Cancer Genet Cytogenet       Date:  2007-07-15

10.  MTUS1 and its targeting miRNAs in colorectal carcinoma: significant associations.

Authors:  Onder Ozcan; Murat Kara; Onder Yumrutas; Esra Bozgeyik; Ibrahim Bozgeyik; Ozgur Ilhan Celik
Journal:  Tumour Biol       Date:  2015-12-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.